XT
RNAM

XTX Topco’s Avidity Biosciences RNAM Stock Holding History

XTX Topco’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,652
Closed -$682K – 3715
2025
Q3 		$682K Buy
+15,652
New +$633K 0.04% 843
2025
Q1 		– Sell
-8,889
Closed -$258K – 2995
2024
Q4 		$258K Buy
8,889
+2,852
+47% +$119K 0.02% 1346
2024
Q3 		$277K Buy
+6,037
New +$262K 0.02% 1238
2024
Q2 		– Sell
-10,055
Closed -$257K – 2383
2024
Q1 		$257K Buy
+10,055
New +$158K 0.03% 979
2023
Q4 		– Sell
-60,731
Closed -$387K – 2049
2023
Q3 		$387K Buy
+60,731
New +$523K 0.07% 556
2023
Q2 		– Sell
-12,919
Closed -$198K – 1770
2023
Q1 		$198K Buy
12,919
+1,857
+17% +$40.9K 0.04% 966
2022
Q4 		$245K Buy
11,062
+924
+9% +$13.8K 0.05% 712
2022
Q3 		$166K Buy
+10,138
New +$194K 0.04% 843

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

XTX Topco's RNAM Position: Q4 2025 in Review

XTX Topco sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 15,652 shares — an estimated $682K sold.

XTX Topco first reported a position in RNAM in Q3 2022 and held it in 8 quarters. The position peaked at $682K in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • XTX Topco reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • XTX Topco sold 15,652 Avidity Biosciences shares in Q4 2025, an estimated $682K.
  • XTX Topco first reported a position in Avidity Biosciences in Q3 2022 and held it in 8 quarters.
  • XTX Topco's Avidity Biosciences position peaked at $682K in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on XTX Topco's 13F filing for Q4 2025, filed 17 Feb 2026.